Amyloid-B peptide (AB) is believed to have a central role in the pathogenesis of Alzheimer's disease (AD). Intracellular mechanisms by which AB disrupts cellular properties, leading to neuronal and synaptic dysfunction, and mitochondrial damage, are not well understood. ABAD (A6 Binding Alcohol Dehydrogenase) is an intracellular enzyme with unique features including a wide range of substrates, binding AB in the nanomolar range, and exacerbating AB-induced cell stress. Recent results from this laboratory and others support a connection between ABAD and AB-mediated mitochondrial and synaptic dysfunction (project 3) relevant to AD pathology. Ap interacts specifically with ABAD in the mitochondria of AD patients and transgenic mice. Transgenic mice overexpressing ABAD in an Ap-rich milieu present exaggerated neuronal oxidative stress, mitochondrial dysfunction, and impaired memory. The crystal structure of Ap-bound ABAD shows substantial deformation of the active site that prevents nicotinamide adenine dinucleotide (NAD) binding. From the crystal structure, the putative AB interaction site in ABAD spans residues 94-114. A peptide encompassing this region of ABAD, residues 91-119, specifically inhibits the ABAD-Ap interaction and suppresses Ap-induced apoptosis and free- radical generation in neurons. Indicating that binding of ABAD to AB is crucial in AB-mediated neuronal stress. Possible mechanisms underlying ABAD-mediated changes in mitochondrial properties are indicated by our findings that AB inhibits ABAD enzymatic activity, the observation that ABAD binds cyclophilin (cypD), sequestering the latter in the mitochondrial matrix, and potential toxic effects of ABAD-ABcomplex (e.g., generation of ROS). This competitive renewal is founded on the hypothesis that ABAD is a critical intracellular target potentiating AB-mediated mitochondrial dysfunction and, thus, leading to cellular perturbation in an AB-rich environment. Blockade of the ABAD-ABinteraction may be a potential therapeutic approach in the treatment of AD.
The aims of Project 4 are to identify the basis of ABAD-AB, ABAD-cyclophilin D (cypD) interactions using crystal structure techniques, and to analyze critical aspects of the intracellular pathway through which ABAD engages AB, cypD, and ABAD-AB complex induces cellular stress. Project 4 will work closely with Projects 1-3, and will obtain technical assistancefrom CoreA. Collaborative interactions will include: sharing of reagents for analysis of ABAD (Project 3), mechanisms for evaluating cell stress (Projects 1-3), and assistance in data analysis (core A).

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG017490-08
Application #
7632193
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2008-07-01
Budget End
2009-06-30
Support Year
8
Fiscal Year
2008
Total Cost
$308,671
Indirect Cost
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Juranek, Judyta K; Daffu, Gurdip K; Geddis, Matthew S et al. (2016) Soluble RAGE Treatment Delays Progression of Amyotrophic Lateral Sclerosis in SOD1 Mice. Front Cell Neurosci 10:117
Carlson, Emily A; Marquez, Rebecca T; Du, Fang et al. (2015) Overexpression of 17?-hydroxysteroid dehydrogenase type 10 increases pheochromocytoma cell growth and resistance to cell death. BMC Cancer 15:166
Du, Heng; Guo, Lan; Wu, Xiaoping et al. (2014) Cyclophilin D deficiency rescues A?-impaired PKA/CREB signaling and alleviates synaptic degeneration. Biochim Biophys Acta 1842:2517-27
Juranek, Judyta K; Geddis, Matthew S; Rosario, Rosa et al. (2013) Impaired slow axonal transport in diabetic peripheral nerve is independent of RAGE. Eur J Neurosci 38:3159-68
Borger, Eva; Aitken, Laura; Du, Heng et al. (2013) Is amyloid binding alcohol dehydrogenase a drug target for treating Alzheimer's disease? Curr Alzheimer Res 10:21-9
Juranek, Judyta K; Geddis, Matthew S; Song, Fei et al. (2013) RAGE deficiency improves postinjury sciatic nerve regeneration in type 1 diabetic mice. Diabetes 62:931-43
Du, Heng; Guo, Lan; Yan, Shirley ShiDu (2012) Synaptic mitochondrial pathology in Alzheimer's disease. Antioxid Redox Signal 16:1467-75
Huang, Tianwen; Fang, Fang; Chen, Limin et al. (2012) Ginsenoside Rg1 attenuates oligomeric A?(1-42)-induced mitochondrial dysfunction. Curr Alzheimer Res 9:388-95
Carnevale, Daniela; Mascio, Giada; D'Andrea, Ivana et al. (2012) Hypertension induces brain ?-amyloid accumulation, cognitive impairment, and memory deterioration through activation of receptor for advanced glycation end products in brain vasculature. Hypertension 60:188-97
Yan, Shirley ShiDu; Chen, Doris; Yan, Shiqian et al. (2012) RAGE is a key cellular target for Abeta-induced perturbation in Alzheimer's disease. Front Biosci (Schol Ed) 4:240-50

Showing the most recent 10 out of 68 publications